Enstamont B Tablet is a combination pharmaceutical formulation containing Bilastine 20mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Bilastine, a second-generation antihistamine, selectively antagonizes peripheral H1 histamine receptors, thereby alleviating symptoms like sneezing, nasal congestion, rhinorrhea, and itching without causing significant sedation. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor CysLT1, reducing airway inflammation and bronchoconstriction commonly associated with allergic responses and asthma. The synergistic action of these two agents provides comprehensive relief from both immediate and delayed allergic symptoms. Enstamont B is typically administered orally once daily, with or without food, as prescribed by a healthcare professional. It is well-tolerated, with a low incidence of adverse effects, though patients should be monitored for potential hypersensitivity reactions or neuropsychiatric events. Caution is advised in patients with hepatic impairment or those taking concomitant medications metabolized via cytochrome P450 pathways. Enstamont B Tablet offers an effective therapeutic option for patients requiring combined antihistaminic and leukotriene receptor antagonist treatment to improve quality of life in allergic disorders.